A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is
The recent description of the mechanism of action of metformin at the cellular level offers the opportunity to revisit the question of whether or not metformin is beneficial in patients with atherosclerotic cardiovascular disease (ASCVD). In the context of newer, larger trials which examined the role of glycemic management in high risk patients with diabetes, the landmark UK Prospective Diabetes Study (UKPDS) and University Group Diabetes Program (UGDP) study are revisited. A closedoi:10.15761/cdm.1000152 fatcat:ulg6olpfenb6fn4rbnk2243peu